Literature DB >> 8407224

Expression of glial fibrillary acidic protein in rabbit Müller cells after lensectomy-vitrectomy.

A Yoshida1, S Ishiguro, M Tamai.   

Abstract

PURPOSE: To assess retinal response after lensectomy-vitrectomy, the authors analyzed glial fibrillary acidic protein (GFAP), which retinal glial cells express in several pathologic conditions.
METHODS: GFAP expression was examined by means of immunohistochemistry, Western blot analysis, and enzyme-linked immunosorbent assay (ELISA) in rabbit retina after lensectomy-vitrectomy.
RESULTS: Müller cells had detectable GFAP immunoreactivity in peripheral retina 3 days after surgery. GFAP immunoreactivity was present in both peripheral and posterior regions 7 days, 14 days, and 6 months after surgery. The authors confirmed that anti-GFAP antibody recognized the 51 kDa protein specifically by Western blot analysis. Time-dependent increase of GFAP in peripheral retina was also obtained by ELISA:
CONCLUSIONS: Such progressive GFAP accumulation in Müller cells, which are sensitive to microenvironmental changes, may reflect some underlying retinal response after lensectomy-vitrectomy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8407224

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  Tailored vitrectomy and laser photocoagulation without scleral buckling for all primary rhegmatogenous retinal detachments.

Authors:  K Johansson; M Malmsjö; F Ghosh
Journal:  Br J Ophthalmol       Date:  2006-07-12       Impact factor: 4.638

2.  Lensectomy and vitrectomy decrease the rate of photoreceptor loss in rhodopsin P347L transgenic pigs.

Authors:  Tamer H Mahmoud; Brooks W McCuen; Ying Hao; Suk J Moon; Misako Tatebayashi; Sandra Stinnett; Robert M Petters; Fulton Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-03-21       Impact factor: 3.117

3.  Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis.

Authors:  Dennis P Han
Journal:  Trans Am Ophthalmol Soc       Date:  2004

4.  Time course of growth factor staining in a rabbit model of traumatic tractional retinal detachment.

Authors:  I Westra; S G Robbins; D J Wilson; J E Robertson; L M O'Rourke; C E Hart; J T Rosenbaum
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-09       Impact factor: 3.117

5.  Selective removal of photoreceptor cells in vivo using the biodegradable elastomer poly(glycerol sebacate).

Authors:  Fredrik Ghosh; William L Neeley; Karin Arnér; Robert Langer
Journal:  Tissue Eng Part A       Date:  2009-04-03       Impact factor: 3.845

6.  Long-term neuroretinal full-thickness transplants in a large animal model of severe retinitis pigmentosa.

Authors:  Fredrik Ghosh; Karl Engelsberg; Robert V English; Robert M Petters
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-27       Impact factor: 3.535

7.  Delivery of Topically Applied Calpain Inhibitory Peptide to the Posterior Segment of the Rat Eye.

Authors:  Taku Ozaki; Mitsuru Nakazawa; Tetsuro Yamashita; Sei-Ichi Ishiguro
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

8.  Peripapillary Intravitreal Injection Improves AAV-Mediated Retinal Transduction.

Authors:  Sanjar Batirovich Madrakhimov; Jin Young Yang; Dong Hyuck Ahn; Jung Woo Han; Tae Ho Ha; Tae Kwann Park
Journal:  Mol Ther Methods Clin Dev       Date:  2020-03-30       Impact factor: 6.698

9.  Presumed activated retinal astrocytes and Müller cells in healthy and glaucomatous eyes detected by spectral domain optical coherence tomography.

Authors:  Hin Cheung; Brett J King; Thomas J Gast
Journal:  Ophthalmic Physiol Opt       Date:  2020-09-04       Impact factor: 3.117

10.  A sustained dual drug delivery system for proliferative vitreoretinopathy.

Authors:  Ying Xiao; Kyung Seek Choi; David Warther; Kristyn Huffman; Stephanie Landeros; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.